Healthcare Roundup – Trump taking Regeneron antibody cocktail, Study of AstraZeneca COVID-19 vaccine resumes in Japan
Trump taking Regeneron antibody cocktail
President Donald Trump is taking Regeneron’s (NASDAQ:REGN) antibody cocktail after testing positive for COVID-19, a memo from his physician says.
“Following PCR-confirmation of the President’s diagnosis, as a precautionary measure he received a single 8 gram dose of Regeneron’s polyclonal antibody cocktail,” Dr. Sean P. Conley writes. “He completed the infusion without incident.”
NAI500 seeks to provide the most pressing investment knowledge to its readers. On October 7 and 8, NAI500 is hosting a FREE VIRTUAL EVENT focusing on the rapidly growing mining sector. Learn about Gold and Precious Metals Exploration, Battery Metals and much more by registering here.
Trump is described as “fatigued but in good spirits”.
First Lady Melania Trump “remains well with only a mild cough and headache”.
The cocktail recently showed benefits in non-hospitalized patients.
Regeneron is +3.2% after hours.
Study of AstraZeneca COVID-19 vaccine resumes in Japan
Following a review of safety data by an independent committee, a Phase 3 clinical trial evaluating AstraZeneca’s (NASDAQ:AZN) COVID-19 vaccine candidate, AZD1222, has resumed in Japan following earlier restarts in the U.K., Brazil, South Africa and India.
The U.S. study has yet to resume.
Bristol Myers wins FDA OK for mesothelioma drug combo treatment
Bristol Myers Squibb (NYSE:BMY) says it received Food and Drug Administration approval for the drug combination of Opdivo and Yervoy for use in treatment of adults with malignant pleural mesothelioma.
The approval is based on a pre-specified interim analysis from a phase 3 trial in which Opdivo plus Yervoy demonstrated superior overall survival vs. the platinum-based standard of care chemotherapy.
Malignant pleural mesothelioma is a rare cancer of the lungs’ lining due to the inhaling of asbestos fibers.
Merger benefits from Celgene are still set to boost Bristol Myers’ earnings estimates, and the shares are too cheap at only 8x 2022 EPS estimates, Stone Fox Capital says in a bullish analysis posted recently on Seeking Alpha.
COVID-19 vaccine developers little changed on news of Trump/First Lady infection
Investors in COVID-19 vaccine and therapy developers appear unmoved with the news that President Trump and First Lady Melania have both tested positive for the respiratory infection and will begin quarantine immediately.
Selected tickers: Sanofi (NASDAQ:SNY) (-1%), GlaxoSmithKline (NYSE:GSK) (up a fraction), AstraZeneca (NASDAQ:AZN) (up a fraction), Merck (NYSE:MRK) (down a fraction), Johnson & Johnson (NYSE:JNJ) (-1%), Moderna (NASDAQ:MRNA) (-1%), Pfizer (NYSE:PFE) (-1%), BioNTech SE (NASDAQ:BNTX) (+1%), Dynavax (NASDAQ:DVAX) (-2%), Novavax (NASDAQ:NVAX) (-1%), Gilead Sciences (NASDAQ:GILD) (up a fraction), Eli Lilly (NYSE:LLY) (-1%); Regeneron Pharmaceuticals (NASDAQ:REGN) (-1%)
Teva launches first generic versions of HIV-1 treatments in U.S.
Teva Pharmaceuticals (NYSE:TEVA) announces the availability of the first FDA-approved generic versions of Gilead Sciences’ (NASDAQ:GILD) TRUVADA (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) and ATRIPLA (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) tablets.
These newly available generic medicines are indicated for the treatment of HIV-1 infection or HIV-1 pre-exposure prophylaxis when used alone or in combination with other anti-HIV-1 medicines.
Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are expected to be available at $48.51 per tablet.
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets will be available at a price of $78.86/tablet.
Shares are down 2% premarket.